We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+13.45%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$3.13B
AUM Growth
+$403M
Cap. Flow
+$107M
Cap. Flow %
3.43%
Top 10 Hldgs %
44.51%
Holding
113
New
15
Increased
22
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
BNTC icon
Benitec Biopharma
BNTC
+$63.9M
2
SBUX icon
Starbucks
SBUX
+$47.2M
3
CRWD icon
CrowdStrike
CRWD
+$34.7M
4
COF icon
Capital One
COF
+$33.5M
5
BIOA
BioAge Labs
BIOA
+$29.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$65.4M
2
ACLX
Arcellx
ACLX
+$55M
3
ELV icon
Elevance Health
ELV
+$49.5M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$46.4M
5
SYY icon
Sysco
SYY
+$37.2M

Sector Composition

Rank Sector Weight
1 Healthcare 53.04%
2 Technology 9.98%
3 Consumer Discretionary 7.64%
4 Communication Services 6.42%
5 Financials 4.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$316M 10.1%
550,000
+50,000
+10% +$27.6M
BHVN icon
2
Biohaven
BHVN
$2.16B
$260M 8.31%
5,199,219
– –
KURA icon
3
Kura Oncology
KURA
$922M
$150M 4.78%
7,652,782
+583,155
+8% +$11.8M
INSM icon
4
Insmed
INSM
$23.2B
$119M 3.82%
1,635,709
-886,091
-35% -$65.4M
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$105M 3.37%
1,439,026
-126,970
-8% -$9.54M
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$3.42B
$99.7M 3.19%
10,721,511
+717,019
+7% +$7.08M
META icon
7
Meta Platforms (Facebook)
META
$1.51T
$96.4M 3.09%
168,488
+1,319
+0.8% +$679K
UNH icon
8
UnitedHealth
UNH
$382B
$85.9M 2.75%
146,845
-14,623
-9% -$8.27M
BNTC icon
9
Benitec Biopharma
BNTC
$394M
$81.1M 2.6%
8,829,053
+7,137,763
+422% +$63.9M
AAPL icon
10
Apple
AAPL
$4.89T
$78.3M 2.51%
336,147
-27,210
-7% -$6.08M
AMZN icon
11
Amazon
AMZN
$2.5T
$65.6M 2.1%
352,069
-4,199
-1% -$766K
RARE icon
12
Ultragenyx Pharmaceutical
RARE
$2.65B
$64M 2.05%
1,151,314
-910,112
-44% -$46.4M
TSM icon
13
TSMC
TSM
$2.09T
$60.6M 1.94%
348,742
-2,010
-0.6% -$343K
ETNB
14
DELISTED
89bio
ETNB
$59.1M 1.89%
7,991,644
-40,201
-0.5% -$338K
APO icon
15
Apollo Global Management
APO
$70.7B
$58.1M 1.86%
465,050
+110,564
+31% +$12.8M
ACLX
16
DELISTED
Arcellx
ACLX
$57.6M 1.84%
689,950
-826,304
-54% -$55M
AMD icon
17
Advanced Micro Devices
AMD
$851B
$56.9M 1.82%
346,575
+577
+0.2% +$87.7K
SBUX icon
18
Starbucks
SBUX
$118B
$53.6M 1.72%
+550,309
New +$47.2M
GS icon
19
Goldman Sachs
GS
$313B
$53.6M 1.72%
108,308
+30,360
+39% +$14.8M
RPRX icon
20
Royalty Pharma
RPRX
$26.1B
$52.8M 1.69%
1,866,361
– –
TSLA icon
21
Tesla
TSLA
$1.24T
$50.7M 1.62%
193,842
+58,929
+44% +$13.4M
T icon
22
AT&T
T
$165B
$50.3M 1.61%
2,285,336
+98,450
+5% +$1.96M
CRH icon
23
CRH
CRH
$66.7B
$50M 1.6%
538,894
+106,910
+25% +$8.98M
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$48.8M 1.56%
4,212,005
+20,000
+0.5% +$252K
FERG icon
25
Ferguson
FERG
$44.7B
$44.7M 1.43%
225,210
+80,170
+55% +$16.2M
1
2 3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return

Suvretta Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Suvretta Capital Management held 113 positions worth $3.13B, up 15% from $2.72B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Suvretta Capital Management deployed $107M of net new capital in Q3 2024, opening 15 new positions and adding to 22 existing holdings. Its largest new stake was Starbucks: 550,309 shares worth $53.6M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, down from 59% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Insmed, an estimated $65.4M trimmed.

  • Suvretta Capital Management's largest Q3 2024 buy was Starbucks: 550,309 shares worth $53.6M.
  • Suvretta Capital Management added most to Benitec Biopharma in Q3 2024, an estimated $63.9M increase.
  • Suvretta Capital Management's biggest Q3 2024 reduction was Insmed, cutting an estimated $65.4M.
  • Suvretta Capital Management fully exited Elevance Health in Q3 2024, selling an estimated $49.5M.
  • Suvretta Capital Management's ten largest holdings make up 45% of its $3.13B portfolio in Q3 2024.
  • Suvretta Capital Management opened 15 new positions and closed 15 in Q3 2024.
  • Suvretta Capital Management's portfolio value rose 15% quarter-over-quarter to $3.13B.

Based on Suvretta Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.